<DOC>
	<DOC>NCT02304198</DOC>
	<brief_summary>This study evaluates the long-term safety of Udenafil in Patient with Pulmonary Arterial Hypertension(PAH). All the patients will receive Udenafil for 1-year(48-weeks).</brief_summary>
	<brief_title>Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH</brief_title>
	<detailed_description>Pulmonary arterial Hypertension is characterized by a progressive incerease in pulmonary vascular resistance(PVR) leading to right ventricualar failure. Udenafil inhibits PDE 5, an enzyme that metabolizes cGMP, enhancing the cGMP mediated relaxation and growth inhibition of vascular smooth muscle cells, including those in the lung.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>Patients who completed the initial study(DA8159_PAH_II), 12week, doubleblind, placebocontrolled trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>